scholarly journals Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

2013 ◽  
Vol 3 (6) ◽  
pp. e121-e121 ◽  
Author(s):  
P Razavi ◽  
K A Rand ◽  
W Cozen ◽  
A Chanan-Khan ◽  
S Usmani ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Novel Therapeutics ◽  
Malignancy Risk ◽  
Before And After

Observations of Second Primary Malignancy in Patients With Multiple Myeloma

2012 ◽  
Vol 12 (2) ◽  
pp. 113-117 ◽  
Author(s):  
Anne Ormerod ◽  
Christopher A. Fausel ◽  
Rafat Abonour ◽  
Patrick J. Kiel
Keyword(s):  
Multiple Myeloma ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Abdullah M. Khan ◽  
Jameel Muzaffar ◽  
Hermant Murthy ◽  
John R. Wingard ◽  
Jan S. Moreb
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Acute Lymphoblastic Leukemia ◽  
Bone Marrow Biopsy ◽  
Lymphoblastic Leukemia ◽  
Second Primary ◽  
Cell Transplant ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Prognostic Features

Lenalidomide maintenance following autologous stem cell transplant (ASCT) is considered the standard of care for eligible patients with multiple myeloma (MM). A recent meta-analysis has provided additional evidence that lenalidomide maintenance is associated with a higher incidence of second primary malignancies, including both hematologic and solid malignancies. Acute lymphoblastic leukemia (ALL) as a second primary malignancy is rarely described in the literature. Herein, we describe two patients with MM treated with induction therapy, ASCT, and lenalidomide maintenance that experienced cytopenias while on maintenance. ALL was unexpectedly diagnosed on bone marrow biopsy. One patient was diagnosed on routine biopsy performed as part of requirements of the clinical trial. Both patients had B-cell ALL, without known poor risk cytogenetics, and were managed with standard induction therapies resulting in complete remission. We also reviewed the literature for similar cases of secondary ALL (sALL) in MM patients exposed to immunomodulatory drugs (IMiDs). In conclusion, persistent cytopenias in responding MM patients receiving IMiDs maintenance should be an indication for bone marrow biopsy. Patients develop sALL after median of 32.5 months (range, 20–84) from being on lenalidomide or thalidomide maintenance, often presenting with cytopenias, display low tolerance to chemotherapy, but remission can often be achieved.

scholarly journals Second primary malignancy after multiple myeloma-population trends and cause-specific mortality

2018 ◽  
Vol 182 (4) ◽  
pp. 513-520 ◽  
Author(s):  
Luciano J. Costa ◽  
Kelly N. Godby ◽  
Saurabh Chhabra ◽  
Robert Frank Cornell ◽  
Parameswaran Hari ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Population Trends ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Specific Mortality

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Blood ◽  
2012 ◽  
Vol 119 (12) ◽  
pp. 2764-2767 ◽  
Author(s):  
Meletios A. Dimopoulos ◽  
Paul G. Richardson ◽  
Nancy Brandenburg ◽  
Zhinuan Yu ◽  
Donna M. Weber ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Pooled Analysis ◽  
Second Primary ◽  
Separate Analysis ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Pivotal Phase ◽  
Refractory Multiple Myeloma ◽  
Skin Cancers ◽  
Second Primary Malignancies

Abstract In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3.62. IR of invasive (hematologic and solid tumor) SPMs was 2.08, consistent with the background incidence of developing cancer. In a separate analysis of pooled data from pivotal phase 3 trials of relapsed or refractory MM (N = 703), the overall IR of SPMs was 3.98 (95% confidence interval [CI], 2.51-6.31) with lenalidomide/dexamethasone and 1.38 (95% CI, 0.44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) and 0.91 (95% CI, 0.23-3.66), respectively; IRs of invasive SPMs were 1.71 (95% CI, 0.86-3.43) and 0.91 (95% CI, 0.23-3.66), respectively. The risk of SPMs must be taken into account before initiating lenalidomide treatment. In the context of the observed survival benefit in relapsed or refractory MM patients, the benefit/risk profile of lenalidomide/dexamethasone remains positive.

scholarly journals Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis

Thyroid ◽  
2009 ◽  
Vol 19 (5) ◽  
pp. 451-457 ◽  
Author(s):  
Anna M. Sawka ◽  
Lehana Thabane ◽  
Luciana Parlea ◽  
Irada Ibrahim-Zada ◽  
Richard W. Tsang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Radioactive Iodine ◽  
Meta Analysis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk ◽  
Iodine Treatment

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma

Leukemia ◽  
2018 ◽  
Vol 33 (1) ◽  
pp. 266-270 ◽  
Author(s):  
Ibrahim Aldoss ◽  
Marzia Capelletti ◽  
Jihye Park ◽  
Romanos Sklavenitis Pistofidis ◽  
Raju Pillai ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy
Sign in / Sign up

Export Citation Format

Share Document